C-Stem™ generates scale-independent cell culture micro-environments, allowing to progress to larger bioreactors without changing key parameters.
C-Stem™ perserves genomic integrity and yields mature cell phenotypes, thereby enhancing the safety of cellular products
C-Stem™ delivers functional microtissues, which were shown to improve graft integration and reduce time-to-effect.
A 3D stem cell biology team with a dedicated R&D platform adapts existing protocols to C-Stem™ for optimal hPSC amplfication and differentiation
A bioproduction team develops bioreactor-based manufacturing processes to secure commercial-scale batches for non-clinical and early clinical phases
Our scientists bring expertise in logistics, delivery formats and medical devices to maximize the clinical convenience and therapeutic benefits of the product
Our encapsulation and analytical development teams provide continuous support for the optimization of manufacturing processes
TreeFrog Therapeutics has developed C-Stem, a technology allowing for the mass-production of iPS-derived cell therapies in large-scale bioreactors. C-stem is based on a proprietary high-throughput cell encapsulation technology which generates over 1,000 capsules per second. Each stem cell capsule constitutes a biomimetic micro-environment which recapitulates an in-vivo like stem cell niche. In the capsule, pluripotent stem cells self-organize to form an epiblast-like 3D stem cell microtissue which promotes exponential pluripotent stem cell growth, maintenance of homogenous pluripotency and high-fidelity chromosome segregation (preservation of genomic integrity). But the capsule is also protecting stem cells during manufacturing proceses. In fact, C-Stem allows for the scale-independent exponential amplification of hiPSCs and their differentiation into functional 3D microtissues in industrial bioreactors.